Literature DB >> 29700696

The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

Armando Tripodi1, Francesco Marongiu2, Marco Moia3, Gualtiero Palareti4, Vittorio Pengo5, Daniela Poli6, Domenico Prisco7, Sophie Testa8, Maria Zanazzi9.   

Abstract

Direct oral anticoagulants (DOAC) possess high bioavailability, and their anticoagulant effect is more predictable than that of vitamin K antagonists, hence they do not require routine dose adjustment based on laboratory testing. However, there are circumstances when laboratory testing may be useful, including patients who need to undergo surgery or invasive procedures. Most guidelines state that patients on DOAC may safely undergo surgery/invasive procedures by stopping anticoagulation for a few days before intervention without testing if renal function is within normal limits. This review article discusses the pros and cons of measuring (or not measuring) DOAC levels before surgery/invasive procedures by a multidisciplinary team of experts with different background, including the thrombosis laboratory, clinical thrombosis, internal medicine, cardiology and nephrology. The conclusion is that measuring DOAC with dedicated tests before surgical or invasive procedures is important for patient safety. It provides the best and most direct evidence to rule in (or to rule out) clinically relevant concentrations of residual drugs. Regulatory agencies should urgently approve their use in clinical practice. Hospital administrators should make them available, and clinical laboratories should set up the relative methods and make them available to clinicians.

Entities:  

Keywords:  Anticoagulation; Bleeding; Direct oral anticoagulants; Invasive procedure; Laboratory testing; Surgery

Mesh:

Substances:

Year:  2018        PMID: 29700696     DOI: 10.1007/s11739-018-1854-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  44 in total

1.  Correlating prothrombin time with plasma rivaroxaban level.

Authors:  Ryan Rodgers; Catherine N Bagot; Caroline Lawrence; Grainne Hickman; Michael McGurk; Robert Campbell Tait
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

Review 2.  The laboratory and the direct oral anticoagulants.

Authors:  Armando Tripodi
Journal:  Blood       Date:  2013-04-05       Impact factor: 22.113

3.  Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure.

Authors:  J D Douketis; G Wang; N Chan; J W Eikelboom; S Syed; R Barty; K A Moffat; F A Spencer; M Blostein; S Schulman
Journal:  J Thromb Haemost       Date:  2016-01-04       Impact factor: 5.824

4.  To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment.

Authors:  A C Spyropoulos; A Al-Badri; M W Sherwood; J D Douketis
Journal:  J Thromb Haemost       Date:  2016-10-24       Impact factor: 5.824

5.  Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.

Authors:  S Testa; C Legnani; A Tripodi; O Paoletti; V Pengo; R Abbate; L Bassi; P Carraro; M Cini; R Paniccia; D Poli; G Palareti
Journal:  J Thromb Haemost       Date:  2016-10-15       Impact factor: 5.824

6.  Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants.

Authors:  Geoffrey D Barnes; Brahmajee K Nallamothu; Anne E Sales; James B Froehlich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-03-01

Review 7.  Heart Failure and Kidney Disease.

Authors:  Dario Grande; Margherita Ilaria Gioia; Paola Terlizzese; Massimo Iacoviello
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.

Authors:  H Tran; J Joseph; L Young; S McRae; J Curnow; H Nandurkar; P Wood; C McLintock
Journal:  Intern Med J       Date:  2014-06       Impact factor: 2.048

Review 9.  The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.

Authors:  Raza Alikhan; Rachel Rayment; David Keeling; Trevor Baglin; Gary Benson; Laura Green; Scott Marshall; Raj Patel; Sue Pavord; Peter Rose; Campbell Tait
Journal:  Emerg Med J       Date:  2013-02-22       Impact factor: 2.740

Review 10.  DOACs - advances and limitations in real world.

Authors:  Lai Heng Lee
Journal:  Thromb J       Date:  2016-10-04
View more
  7 in total

1.  Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Authors:  Sophie Testa; Walter Ageno; Emilia Antonucci; Rossella Morandini; Jan Beyer-Westendorf; Maurizio Paciaroni; Marc Righini; Piera Sivera; Peter Verhamme; Vittorio Pengo; Daniela Poli; Gualtiero Palareti
Journal:  Intern Emerg Med       Date:  2018-05-22       Impact factor: 3.397

2.  Direct oral anticoagulants in lipoprotein apheresis: handle with care.

Authors:  Francesco Sbrana; Beatrice Dal Pino; Angela Papa; Federico Bigazzi; Luca Panchetti; Tiziana Sampietro
Journal:  Intern Emerg Med       Date:  2019-06-04       Impact factor: 3.397

3.  A focus on direct oral anticoagulants: "old" and possible new indications and efforts for a better clinical management.

Authors:  Domenico Prisco
Journal:  Intern Emerg Med       Date:  2018-09-21       Impact factor: 3.397

4.  A clinical conundrum: to measure or not measure direct oral anticoagulants before a surgery or procedure?

Authors:  James D Douketis; Mansoor Radwi
Journal:  Intern Emerg Med       Date:  2018-08-24       Impact factor: 3.397

5.  Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.

Authors:  Elvira Grandone; Filippo Aucella; Doris Barcellona; Giuliano Brunori; Giacomo Forneris; Paolo Gresele; Marco Marietta; Daniela Poli; Sophie Testa; Armando Tripodi; Simonetta C Genovesi
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

Review 6.  Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction.

Authors:  Balbir Singh; Paresh Pai; Harish Kumar; Sheeba George; Sandeep Mahapatra; Vineet Garg; G N Gupta; Kiran Makineni; Gaurav Ganeshwala; Pravin Narkhede; Syed M H Naqvi; Kumar Gaurav; Mohammed Y K Hukkeri
Journal:  Cardiol Ther       Date:  2022-02-08

7.  Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).

Authors:  Elvira Grandone; Filippo Aucella; Doris Barcellona; Giuliano Brunori; Giacomo Forneris; Paolo Gresele; Marco Marietta; Daniela Poli; Sophie Testa; Armando Tripodi; Simonetta Genovesi
Journal:  J Nephrol       Date:  2020-07-31       Impact factor: 3.902

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.